Innovation is the key to success for any pharmaceutical or biotechnology company. Equally important is procuring intellectual property to safeguard those innovations and developing strategies to protect those valuable assets from unauthorized use by competitors. Our team has the litigation experience, patent proficiency and regulatory knowledge to do just that.
Industry leaders have relied on us to ward off challenges from generic competitors in more than 170 ANDA litigations in the past five years alone, making us one of the most seasoned teams in the field with expertise in various types of Orange Book listed patents. In 2022, LMG Life Sciences named WilmerHale the Hatch-Waxman Litigation Firm of the Year. We are also at the forefront of Biologics Price Competition and Innovation Act (BPCIA) litigation, having represented clients in the first BPCIA-related case ever decided by the US Supreme Court and some of the first BPCIA cases in the District of Delaware.
Life science companies trust us because our lawyers have extensive experience working with companies both large and small to protect their assets around the globe. Our team includes attorneys with deep scientific knowledge in a variety of arts. Because we have more than 100 lawyers with scientific and technical backgrounds, our clients trust us to truly understand their innovations and the business concerns related to their intellectual property. We understand the intricacies of compound, formulation and method-of-treatment patents, as well as best strategies for defending the patent estates of biologics products. We also build teams to include experienced antitrust and transactional lawyers who can offer advice with respect to agreements. Our attorneys take a unique multidisciplinary approach to staffing cases: each is handled by both skilled litigators and lawyers with deep technical knowledge, who also work efficiently with colleagues across practices to achieve results for clients ranging from Fortune 500 companies to startups.